DDInter1616 DDInter1147
Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Romidepsin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Romidepsin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nifedipine
Romidepsin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Histrelin
Romidepsin {u} may lead to a major life threatening interaction when taken with {v} Bacillus calmette-guerin substrain tice live antigen
Romidepsin {u} may lead to a major life threatening interaction when taken with {v} Halofantrine
Romidepsin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Romidepsin may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Romidepsin may lead to a major life threatening interaction when taken with Halofantrine